Google AI
The Times Australia

Times Media Advertising

Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program-PR Newswire APAC

HONG KONG, Nov. 16, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the recipients of its first Asia HIV Research Scholar Program ("Program"). The Program awards up to US$130,000 over a period of two years to support innovative HIV scientific research led by early-career researchers from academic institutions in Asia.

"We are pleased to bring the Program to Asia to foster innovation in HIV to address clinical challenges faced by this region. At Gilead, we believe in supporting the brightest minds, especially early career scientists, as they bring new and local perspectives to push science forward for the communities we serve," said Dr Kuan-Yeh Lee, Director of HIV Medical Affairs, Asia, Gilead Sciences. "The recipients of the HIV research scholar program have shown ingenuity with exciting projects that can potentially break ground in HIV."

The Program is designed to support basic and clinical research in the field of HIV in areas that include, but are not limited to: HIV treatment and management, HIV prevention, HIV and its complications in specific populations (aging population, women, particular racial groups, etc.) as well as translational research related to HIV. It has received competitive submissions from junior faculty researchers from across Mainland China, Hong Kong/Macau, Japan, Singapore, South Korea and Taiwan, two of which emerged as winners of the Program:

  • Takayuki Chikata, PhD, from Kumamoto University, Joint Research Center for Human Retrovirus Infection (Japan), who will focus on identifying and characterizing immune responses among individuals exposed yet tested seronegative to HIV-1, contributing to the development of highly effective vaccines to HIV-1 infection; and
  • Yi-Chia Huang, MD, from "National Taiwan University Hospital Hsin-Chu Branch" (Taiwan), who will be investigating the key immunological profiles that correlate with and may predict serological responses to HBV revaccination among people living with HIV, a population known to be with lower immunogenicity against HBV vaccination.

The Asia HIV Research Scholars Program is part of Gilead's global Research Scholars Program that was launched in 2008 with a mission to support innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet need as well as their career development. All research scholars are selected by an independent panel of scientists who are experts in their field and can retain independence over their projects. To date, the Research Scholars Program has awarded US$29 million to more than 200 scholars around the world across multiple disease areas.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com[1].

About the Gilead Sciences Research Scholars Programs

The Gilead Sciences Research Scholars Programs provide financial support to junior faculty researchers for a two-year period. Each award is funded up to US$130,000, to be paid in annual instalments of up to US$65,000 per year for two years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair. Recipients of these competitive awards are selected by Committees comprised of leaders in the fields of rheumatology, cardiovascular disease, cystic fibrosis, hematology/oncology, HIV, and liver disease. For more information please visit https://researchscholars.gilead.com/[2] 

For more information on Gilead Sciences, please visit the company's website at www.gilead.com[3] or follow Gilead on Twitter (@GileadSciences).[4]

Source: Gilead Sciences, Inc.

References

  1. ^ www.gilead.com (www.gilead.com)
  2. ^ https://researchscholars.gilead.com/ (researchscholars.gilead.com)
  3. ^ www.gilead.com (www.gilead.com)
  4. ^ @GileadSciences (twitter.com)

Read more https://www.prnasia.com/story/archive/3192505_AE92505_0

Business Times

How Do Excavator Mulcher Attachments Simplify Land Clearing and V…

Land clearing and vegetation management are essential activities across construction, agriculture, forestry, utility maintena...

The Businesses That Win First After A Crisis

When a crisis dominates headlines, most business owners focus on survival. Cash flow becomes king. Expansion plans are po...

Click and collect changes the economics of Australian shopping ce…

Australia’s major supermarkets are transforming consumer behaviour through home delivery and click and collect services, bu...

Technology

Why Australian Enterprises Are Reth…

The corporate landscape in Australia has undergone a permanent structural shift over the past few ...

Local News

QLD Day

On Saturday 6 June, parkrun events across the state will be a sea of maroon, with communities  str...

Culture

Ramsay Health Care launches Australian-first …

In an Australian first, an innovative new bladder cancer treatment clinical trial that harnesses t...

Travel

Virgin's Northern Territory Sale Puts th…

Australians thinking about a holiday in the Northern Territory have another reason to start planni...

The Times Features

Virgin's Northern Territory Sale Puts the Spotligh…

Australians thinking about a holiday in the Northern Territory have another reason to start planni...

Australians are tapping housing wealth to stay put and …

Homesafe Wealth Release says More Australians Are Using Housing Wealth to Fund Ageing at Home As mo...

Ramsay Health Care launches Australian-first trial for …

In an Australian first, an innovative new bladder cancer treatment clinical trial that harnesses t...